Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Fractyl Health (GUTS), 977% surge in interest

Pipeline and key clinical candidates for these companies:

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease.

Recent news on these stocks:

September 28

BofA analyst Jason Gerberry raised the firm’s price target on Fractyl Health to $5 from $4 and keeps a Buy rating on the shares. The firm increased the probability of success for Revita to 55% from 20% following the Remain-1 data. The the midpoint analysis of Revita in weight maintenance were better than expected, the analyst tells investors in a research note. The firm says Revita-treated patients lost an additional 2.5% body weight versus sham regaining 10% of body weight at three months and there were no safety red flags.

September 26

Fractyl Health announced results from the REMAIN-1 Midpoint Cohort, supporting the potential for Revita to be the first therapy to preserve weight loss after GLP-1 drug discontinuation. At 3 months, Revita-treated patients lost an additional 2.5% total body weight after stopping tirzepatide, while sham patients regained 10%. These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible. They further support Revita as a potential first-in class treatment in a new therapeutic category in obesity care: post-GLP-1 weight maintenance. Data shared are for the treatment period of up to 3 months. The Midpoint Cohort is ongoing, with 6-month randomized data expected in Q1 2026. Clear evidence of Revita activity: The study met its 3-month efficacy endpoint with strong statistical significance, delivering 2.5% further weight loss with Revita even after stopping tirzepatide, versus 10% weight regain in sham-treated patients. Excellent safety and tolerability through 3 months: No Revita-related SAEs or Grade II+ AEs were observed. Side effects were infrequent, mild, and transient, consistent with prior Revita clinical study experience. Positive readthrough to pivotal study: These data strengthen confidence in the ongoing Pivotal Cohort study, which is on track to complete randomization in early 2026, with 6-month topline primary endpoint data and potential PMA filing expected in H2 2026.

Fractyl Health announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of $1.00 per share. All of the securities are being offered by Fractyl. The gross proceeds from the offering to Fractyl are expected to be approximately $60 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about September 29, 2025, subject to customary closing conditions. BofA Securities and Evercore ISI are acting as joint book-running managers and Ladenburg Thalmann is acting as lead manager for the underwritten offering.

H.C. Wainwright lowered the firm’s price target on Fractyl Health to $8 from $9 and keeps a Buy rating on the shares after Fractyl announced midpoint randomized cohort results from the ongoing REMAIN-1 trial evaluating the Revita DMR procedure for weight loss after GLP-1 RA discontinuation. The change in the firm’s target is based primarily on adjustment of the fully diluted share count following the significant September fundraise and increasing the firm’s projected chance of success for Revita to 60% from 40% based on the positive REMAIN-1 midpoint cohort efficacy and safety results.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.